HUTCHMED (China) Analyst Ratings
HUTCHMED (China) Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 231.24% | Cantor Fitzgerald | → $50 | Reiterates | Overweight → Overweight |
| 07/24/2023 | 231.24% | Cantor Fitzgerald | → $50 | Reiterates | Overweight → Overweight |
| 08/09/2022 | 6% | Goldman Sachs | $14 → $16 | Maintains | Neutral |
| 08/02/2022 | -7.25% | Goldman Sachs | $16 → $14 | Maintains | Neutral |
| 09/22/2021 | 204.74% | Goldman Sachs | → $46 | Downgrades | Buy → Neutral |
| 08/03/2021 | 244.48% | Jefferies | → $52 | Initiates Coverage On | → Buy |
| 03/13/2020 | — | Cantor Fitzgerald | Initiates Coverage On | → Overweight | |
| 02/20/2020 | 151.74% | Goldman Sachs | → $38 | Initiates Coverage On | → Buy |
| 11/19/2019 | — | CLSA | Initiates Coverage On | → Buy | |
| 10/23/2019 | — | B of A Securities | Reinstates | → Buy | |
| 03/04/2019 | — | Deutsche Bank | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/05/2023 | 231.24% | 康托·菲茨杰拉德 | →$50 | 重申 | 超重→超重 |
| 07/24/2023 | 231.24% | 康托·菲茨杰拉德 | →$50 | 重申 | 超重→超重 |
| 08/09/2022 | 6% | 高盛 | $14→$16 | 维护 | 中性 |
| 08/02/2022 | -7.25% | 高盛 | $16→$14 | 维护 | 中性 |
| 09/22/2021 | 204.74% | 高盛 | →$46 | 评级下调 | 购买→中性 |
| 08/03/2021 | 244.48% | 杰富瑞 | →$52 | 开始承保 | →购买 |
| 03/13/2020 | - | 康托·菲茨杰拉德 | 开始承保 | →超重 | |
| 02/20/2020 | 151.74% | 高盛 | →$38 | 开始承保 | →购买 |
| 2019年11月19日 | - | 里昂证券 | 开始承保 | →购买 | |
| 2019年10月23日 | - | B of A证券 | 恢复 | →购买 | |
| 2019/03/04 | - | 德意志银行 | 开始承保 | →购买 |
What is the target price for HUTCHMED (China) (HCM)?
和黄医药(中国)(HCM)的目标价是多少？
The latest price target for HUTCHMED (China) (NASDAQ: HCM) was reported by Cantor Fitzgerald on September 5, 2023. The analyst firm set a price target for $50.00 expecting HCM to rise to within 12 months (a possible 231.24% upside). 2 analyst firms have reported ratings in the last year.
和黄医药(中国)(纳斯达克代码：HCM)的最新目标价是由康托·菲茨杰拉德于2023年9月5日报道的。这家分析公司将目标价定为50美元，预计HCM将在12个月内上涨(可能上涨231.24%)。去年有两家分析公司公布了评级。
What is the most recent analyst rating for HUTCHMED (China) (HCM)?
分析师对和黄医药(中国)的最新评级是多少？
The latest analyst rating for HUTCHMED (China) (NASDAQ: HCM) was provided by Cantor Fitzgerald, and HUTCHMED (China) reiterated their overweight rating.
分析师对和黄医药(中国)(纳斯达克代码：HCM)的最新评级由康托·菲茨杰拉德提供，和黄医药(中国)重申其增持评级。
When is the next analyst rating going to be posted or updated for HUTCHMED (China) (HCM)?
下一次分析师对和黄医药(中国)的评级会在什么时候发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HUTCHMED (China), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HUTCHMED (China) was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
分析师在进行了广泛的研究后得出股票评级，这些研究包括查阅公开财务报表，与和黄医药(中国饰)的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。和黄医药(中国)的上一次评级是在2023年9月5日提交的，所以你应该预计下一次评级将在2024年9月5日左右公布。
Is the Analyst Rating HUTCHMED (China) (HCM) correct?
分析师对和黄医药(中国)的评级正确吗？
While ratings are subjective and will change, the latest HUTCHMED (China) (HCM) rating was a reiterated with a price target of $0.00 to $50.00. The current price HUTCHMED (China) (HCM) is trading at is $15.10, which is within the analyst's predicted range.
虽然评级是主观的，会发生变化，但最新的和黄医药(中国)(HCM)评级被重申，目标价在0.00美元到50.00美元之间。和黄医药(中国)目前的交易价格为15.10美元，在分析师的预测范围内。